Adding focused radiation to EGFR pill and chemo for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding focused radiation therapy to the spots of cancer that remain after your first treatment (an EGFR pill plus chemo) can help control advanced lung cancer better. It is for people whose cancer has an EGFR mutation and who have only a few residual spots, with the goal of delaying progression and improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IV non-small cell lung cancer that has spread.
- Your cancer must have a specific EGFR mutation (either exon 19 deletion or L858R).
- Your first treatment was a third-generation EGFR pill plus chemotherapy, and you completed 4 cycles without the cancer getting worse.
- After those 4 cycles, you have only a few remaining spots of cancer that can be treated with focused radiation.
- You are between 18 and 75 years old and generally in good health (able to do daily activities with some limitations).
- You have no other active cancers, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation therapy to a drug combination can help people with a specific type of lung cancer that has stopped responding to standard first-line pills. It's for patients whose cancer has a certain gene change (EGFR) and has spread to other parts of the body.
This study tests whether adding a precise, high-dose type of radiation (called SBRT or SRS) to the targeted therapy pill osimertinib can better control lung cancer that has an EGFR mutation. If you have had a good response to osimertinib but still have a few remaining tumors, this combination may help improve outcomes.
This trial is testing whether giving focused radiation therapy to the main lung tumor, in addition to standard treatments like targeted therapy or chemo-immunotherapy, can help people with advanced lung cancer that has spread to many places. The goal is to see if adding this radiation can improve outcomes without causing too many side effects.
This study tests whether adding focused radiation to a targeted cancer pill works better than the pill by itself. It is for people with advanced non-small cell lung cancer (NSCLC) whose tumor has an EGFR or ALK/ROS driver mutation and who have not gotten worse after starting the targeted pill.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This Phase 3 study tests whether giving brain radiation early or later, along with almonertinib (a targeted pill), works better for people with EGFR-mutated non-small cell lung cancer that has a small number of brain metastases. It aims to control brain disease while checking safety and effectiveness in a carefully selected group.
Hear when a new SBRT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.